###### Strengths and limitations of this study

-   This review will be the first of its kind to compare different vitamin D dosage schedules (steady vs intermittent bolus dosing schedule).

-   The Bayesian random effect network meta-analysis will be utilised in analysing the direct and indirect treatment effects.

-   This systematic review only includes randomised controlled trials (RCTs) that administered oral vitamin D supplementation; the quality of included RCTs will be assessed and a sensitivity analysis will be performed to investigate the effect of study quality on the overall treatment effect.

-   This systematic review is limited to articles published in English language.

Introduction {#s1}
============

The risk of falls and fractures is a major concern among the ageing population as it can lead to long-term health complications (eg, disability) and pre-mature mortality. Vitamin D is necessary for bone and muscle health,[@R1] and vitamin D deficiency is a risk factor for falls and hip fractures among older adults.[@R1] However, the evidence for the role of vitamin D supplementation in the primary prevention of falls and fractures remains inconclusive.[@R3] To date, randomised clinical controlled trials (RCT) have administered different dosages of vitamin D supplementation with and without calcium, and the evidence for the optimal dosage of vitamin D intake is still largely unresolved.[@R7] Furthermore, the different vitamin D supplementation schedules (ie, daily vs monthly bolus dose) used in previous trials have contributed to the conflicting evidence for the role of vitamin D supplementation in the primary prevention of falls and bone fractures.[@R10] Although, most RCTs and meta-analyses of RCTs have mainly focused on the optimal amount of vitamin D dosage, studies comparing the effectiveness of different dosage schedules have been largely unexplored.

Currently, there is no consensus regarding the optimal vitamin D dosage schedule (ie, frequent and steady vs intermittent high-dose).[@R9] Hollis has previously suggested that steady intake of vitamin D may be more beneficial than intermittent high-dose intake because of the difference produced in serum vitamin D and 25-hydroxyvitamin D (25(OH)D) concentrations.[@R14] A large bolus dose results in a spike in both serum vitamin D and 25(OH)D concentrations and an immediate drop-off in serum vitamin D concentration followed by a more gradual but pronounced drop in 25(OH)D. In contrast, daily dosing schedule results in less pronounced increases and maintains serum vitamin D and 25(OH)D levels over a longer period of time.[@R15] Yet, numerous trials to date have administered bolus dosage schedules (eg, bimonthly, monthly, once every 3--12 months) to increase compliance. Moreover, many published meta-analyses investigating the effects of vitamin D supplementation on skeletal health outcomes have combined daily, weekly, bi-monthly, monthly and large bolus dosage schedules together with some even including high-dose intramuscular injection.[@R3] Vitamin D dosage schedule may be an important factor to consider when assessing the totality of evidence for the beneficial role of vitamin D supplementation in relation to skeletal health outcomes.

The overall objective of this study is to conduct a systematic review and network meta-analysis (NMA) to examine comparative effectiveness and safety of frequent and steady dosage of vitamin D versus intermittent high-dose supplementation, taken alone or in combination with calcium, in reducing the risk of falls and fractures, as well as to explore differences in safety and effectiveness of the different vitamin D dosage schedules (eg, daily, weekly, monthly, every 6 months, yearly).

Methods {#s2}
=======

This protocol is written in accordance with the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols[@R16] and is registered with the PROSPERO database (CRD42018112662, available at: <http://www.crd.york.ac.uk/PROSPERO/display_record.php?ID=CRD42018112662>). Any changes to this protocol will be published in the PROSPERO registration.

Eligibility criteria {#s2-1}
--------------------

### Population {#s2-1-1}

Our study population will include all adults who are 55 years or older or a study population with a mean or median age of 55 years or older, either residing in the community or institutional care settings.

### Interventions {#s2-1-2}

The following vitamin D dosage schedules will be considered for inclusion in our search and subsequent analyses to evaluate comparative efficacy and safety; daily, weekly, bimonthly, monthly, once every 3--12 months intake of oral vitamin D supplementation. We will consider all studies that administer vitamin D alone (either as a supplement or as a fortified food product), or in combination with calcium. For fortified food products, we will only consider RCTs that have administered a vitamin D fortified food product and compare it to an unfortified version of the same product (eg, fortified cheese as the intervention and unfortified cheese as the comparator) to control for any confounding effect from other nutrients when given as a fortified food product.

### Comparators {#s2-1-3}

Eligible comparator groups within studies will include placebo or another form, dosage schedules and combination of vitamin D supplements (ie, daily vitamin D supplementation alone or in combination with calcium will be compared with an intermittent high-dose vitamin D supplementation or in combination with calcium).

Outcomes {#s2-2}
--------

The primary outcomes of treatment efficacy are number of falls, overall fractures, hip fractures, non-vertebral fractures. Secondary outcomes for treatment efficacy will be muscle strength, balance, physical performance, gait and mobility limitations. The primary outcome of treatment safety will be hypercalcaemia. Overall mortality will also be considered as a secondary outcome for treatment safety.

### Study designs {#s2-2-1}

Only RCTs will be included in our systematic review and evidence synthesis. We will consider all designs (eg, cluster, cross-over, etc) and settings (eg, hospital, outpatient, nursing homes). For crossover studies, due to the possibility of a carry-over effect, the Cochrane guideline and recommendations specific to crossover trial will be considered in our analysis.[@R17] Sensitivity analysis will also be performed to investigate the effect of such studies in the overall pooled estimates and comparative rankings.

### Information sources and search strategy {#s2-2-2}

Major medical databases including MEDLINE, EMBASE, CINAHL, Cochrane Central Register of Controlled Trials and ClinicalTrials.gov will be searched systematically to identify all eligible studies. We will also search for additional references through hand-searching the bibliographies of included studies as well as relevant systematic reviews and meta-analyses. Search strategies include various preselected terms and combinations of these terms. These include terms such as vitamin D, vitamin D~3~, vitamin D~2~. Other terms that are used in our search relate to the primary and secondary outcomes and the combination of the outcomes with interventions. The search strategy along with all combination of terms used in our search are shown in [table 1](#T1){ref-type="table"}. All English language studies from conception to 30 April 2018 will be considered; and no restrictions are made on sample size, study period, settings and dosage of vitamin D supplementation. Only human trials involving adults who are 55 years or older or a study population with a mean or median age of 55 years or older will be included.

###### 

Search criteria for the systematic review: EMBASE

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Step                Database: EMBASE\                                                                                                                                                                                                                              Number of papers
                      Search date: 30 April 2018\                                                                                                                                                                                                                    
                      Time/Period: 1974--30 April 2018                                                                                                                                                                                                               
  ------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------
  1                   Vitamin D/ or Vitamin D.mp                                                                                                                                                                                                                     109 558

  2                   Vitamin D2.mp.(mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword, floating subheading word, candidate term word)                                           1760

  3                   Vitamin D3.mp.(mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword, floating subheading word, candidate term word)                                           14 377

  4                   1 or 2 or 3                                                                                                                                                                                                                                    116 444

  5                   Falls.mp.(mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword, floating subheading word, candidate term word)                                                54 525

  6                   Falls.mp. or falling/                                                                                                                                                                                                                          73 654

  7                   5 or 6                                                                                                                                                                                                                                         73 654

  8                   4 and 7                                                                                                                                                                                                                                        2703

  9                   fractures.mp. or fracture                                                                                                                                                                                                                      211 161

  10                  fracture\*.mp.(mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword, floating subheading word, candidate term word)                                           357 706

  11                  9 or 10                                                                                                                                                                                                                                        357 706

  12                  4 and 11                                                                                                                                                                                                                                       15 955

  13                  patient mobility/ or limited mobility/ or Mobility.mp.                                                                                                                                                                                         187 679

  14                  mobility.mp.(mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword, floating subheading word, candidate term word)                                             187 679

  15                  13 or 14                                                                                                                                                                                                                                       187 679

  16                  4 and 15                                                                                                                                                                                                                                       1046

  17                  endurance/ or grip strength/ or physical performance/ or muscle strength/ or Physical Performance\*.mp. or fitness/                                                                                                                            129 167

  18                  Physical Performance\*.mp.(mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword, floating subheading word, candidate term word)                               20 383

  19                  17 or 18                                                                                                                                                                                                                                       129 167

  20                  4 and 19                                                                                                                                                                                                                                       1823

  21                  muscle strength.mp. or muscle strength/                                                                                                                                                                                                        57 550

  22                  muscle strength.mp.(mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword, floating subheading word, candidate term word)                                      57 550

  23                  21 or 22                                                                                                                                                                                                                                       57 550

  24                  4 and 23                                                                                                                                                                                                                                       1302

  25                  gait/ or gait\*.mp.                                                                                                                                                                                                                            79 085

  26                  4 and 25                                                                                                                                                                                                                                       641

  27                  mortality\*.mp.(mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword, floating subheading word, candidate term word) (1 257 640)                              1 257 640

  28                  4 and 27                                                                                                                                                                                                                                       7397

  29                  8 or 12 or 16 or 20 or 24 or 26 or 28                                                                                                                                                                                                          24 342

  ***Limitations***                                                                                                                                                                                                                                                  

  30                  limit 29 to (English language and (clinical trial or randomised controlled trial or controlled clinical trial or multicentre study or phase 1 clinical trial or phase 2 clinical trial or phase 3 clinical trial or phase 4 clinical trial))   4073

  31                  limit 29 to (English language and (meta-analysis or 'systematic review'))                                                                                                                                                                      944

  32                  30 or 31                                                                                                                                                                                                                                       4634
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Data collection and analysis {#s2-3}
----------------------------

### Data management {#s2-3-1}

All abstracts and full text articles will be uploaded to EndNote (V.7) software and all abstracts will be transferred to excel, where screening questions will be developed and tested for Level I and II assessments based on the inclusion and exclusion criteria.

### Study selection {#s2-3-2}

All abstracts of relevant articles will be screened independently by two reviewers (Level I), using the predefined inclusion and exclusion criteria. Our inclusion criteria include RCTs administrating oral dosage of vitamin D supplementation alone or with calcium with no restrictions on the dosage amount of vitamin D or calcium. Studies will be excluded if participants are younger than 55 years of age (mean or median age), study design is observational in nature, and vitamin D is administered via intramuscular injection or vitamin D analogues or combined with other food/drink supplements that are fortified with other nutrients. An initial calibration exercise will be conducted prior to screening to ensure high inter-rater reliability. In these pilot runs, a random sample of 50 included abstracts will be reviewed. Inter-rater agreement will be calculated, and screening will commence when a percentage agreement of at least 80% is observed. If there is poor-moderate agreement (ie, percentage agreement \<80%), the eligibility criteria will be revised, as necessary. Subsequently, each abstract will be screened by two reviewers in duplicate. A similar process will be followed for Level II screening where full texts of the studies retained from the Level I screening will be reviewed. Disagreements at both levels of screening will be resolved by discussion or consultation with a third reviewer.

### Data abstraction {#s2-3-3}

Study and arm level data will be extracted from all studies retained from Level II screening. A pilot assessment involving five studies will be conducted by the two reviewers. The data abstraction form will be reviewed and data abstracted on the five studies will be discussed among team members to ensure all relevant data is being extracted accurately and in a consistent manner among individuals performing data abstraction. The data abstraction form will then be modified as appropriate to ensure clarity and agreement by all team members.

Data will be abstracted on study characteristics such as year of publication, authorship, location(s) of study, journal of publication, settings, latitude, follow-up period, study design (eg, cluster RCT, cross-over), total sample size as well as arm level sample size, patient characteristics \[eg, average (mean or median) age of study population, gender composition, average body mass index (BMI) (or categories)\], living conditions (eg, community dwelling or institution care setting), supplementation details \[eg, vitamin D dose, calcium dose, placebo, dosage schedules (eg, daily, weekly, monthly, every 3--12 months)\], baseline and achieved serum 25(OH)D concentration, if measured. We will also abstract data on the primary and secondary trial-level outcomes associated with supplementation efficacy and safety (eg, falls, injurious falls, overall fractures, hip fractures, non-vertebral fractures, muscle strength, physical performance, gait, mobility limitation, hypercalcaemia, and overall mortality). Data on other relevant comorbidities and treatment related information will also be abstracted (eg, osteoporosis, previous history of fracture, etc). For cluster RCTs, we will also abstract additional information needed to calculate the design effect for making sample size and event level adjustments; these include cluster size, number of clusters, and intra-class correlation coefficient.

### Node formation {#s2-3-4}

The various dosage schedules for vitamin D supplementation, as well as combinations with and without calcium will form nodes for the NMA. We anticipate an initial overall network with minimum of three connected nodes (frequent and steady vitamin D vs high-dose intermittent vitamin D vs placebo). Depending on the search results, heterogeneity across the studies, number of studies within each node as well as validity of other required assumptions for NMA (eg, connectivity, inconsistency, transitivity), we will perform decomposition of the three nodes according, for instance, to dosage schedules (eg, daily, weekly, monthly, etc) and treatment combination (eg, vitamin D alone or in combination with calcium).

### Risk of bias and quality assessment {#s2-3-5}

Two reviewers will independently assess the risk of bias for each included study. This will be done using the Cochrane Risk of Bias Tool.[@R18] Each eligible trial will be assessed for the following domains: random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data addressed and selective reporting.

### Outcome and effect measures {#s2-3-6}

All primary and secondary outcomes are binary. As such, our outcomes are reported in the form of event frequency and sample size at an arm level. Since analysis involves Bayesian NMA, the effect size we will use is the OR.[@R19] For studies not reporting event frequency, any effect measure reported (eg, relative risk, risk difference) will be abstracted and converted back to event frequency or to OR.

### Data synthesis {#s2-3-7}

Data will be first summarised descriptively and with respect to study characteristics, outcomes measures, interventions, patient characteristics as well as other relevant variables. Interventions will be carefully evaluated to clearly identify specific nodes that will be used in the NMA. If feasible (ie, if the network is connected), Bayesian random effects NMA will be conducted to estimate the OR and the corresponding 95% CIs as well as 95% prediction intervals for all comparisons, which will be reported in the form of tables and forest plots.[@R19] We will also estimate treatment rankings with respect to comparative effectiveness and safety; and these will be provided in the form of rank plots. Surface under the cumulative ranking probabilities with the corresponding 95% CIs will be estimated for each treatment and with respect to each of the outcomes.[@R23] A rank-heat plot across all outcomes will also be provided.[@R24]

Prior to conducting NMA, we will perform preliminary analysis to examine the various assumptions required to ensure validity of NMA results. These include checking assumptions of consistency and elucidating homogeneity. As such, we will first investigate global inconsistencies using the design-by-treatment interaction model.[@R25] If inconsistency is detected, we will explore local inconsistencies using the loop-specific approach.[@R26] Data will also be examined for outliers and for potential data errors. We will also explore methodological and statistical heterogeneity as a well as heterogeneity with respect to design, population and setting differences. Statistical heterogeneity will be examined using the I^2^ statistics from all direct (head-to-head) comparisons. Careful considerations (clinical, methodological and statistical) will be done to optimally create the nodes to avoid introducing heterogeneity to the network because of node formation. If significant heterogeneity and/or inconsistency are detected, we will perform meta-regression to elucidate sources of heterogeneity as well as elucidate heterogeneity with respect to known sources of variability (eg, population differences, risk of bias, design differences). We will also perform subgroup analysis to pool estimates from relatively homogenous groups. Sensitivity analyses will also be performed with respect to studies that are deemed to be sources of heterogeneity.

Pair-wise estimates using Bayesian meta-analysis (MA) will also be provided for all comparisons with direct (head-to-head) evidence.[@R20] If NMA is not feasible, pairwise MA will be conducted for interventions with direct evidence only and the results will be presented in the form of forest plots. We will assess for the transitivity assumption to ensure that potential effect modifiers (eg, age, BMI, care settings, study duration) are balanced on average across treatment comparisons. For studies involving cluster RCTs, data will be adjusted using the design effect prior to performing MA and NMA. Meta-regression and/or subgroup analyses will be performed to examine the effect of various effect modifiers.[@R27] These include age, gender, baseline and achieved serum 25(OH)D concentration, BMI categories, form of vitamin D (eg, D~3~ vs D~2~, fortified food vs supplement), co-administration with calcium, comorbidities and settings and study period. We will also conduct sensitivity analysis with respect to risk of bias categories as well as other source of variability revealed from our preliminary analysis to ensure consistency and homogeneity. We will also perform deviance analysis to identify outliers, and sensitivity analysis will be performed to ensure robustness of our results. We will use comparison adjusted funnel plots to investigate presence of publication bias.[@R28]

All NMA and MA analyses will be conducted in WinBUGS Bayesian statistical software.[@R29] Results will be reported as OR along with the 95% CIs based on 100 000 Monte Carlo simulations and vague priors. Mode convergence will be assessed by examining the trace and history plots as well as calculating the Gelmin-Rubin statistic.[@R30] Forest plots and other data analyses will be performed using appropriate packages in the R statistical software.[@R31]

### Patient and public involvement {#s2-3-8}

Patients or the public will not be involved in the design or conduction of this study.

Ethics and dissemination {#s3}
========================

The risk of falls and fractures is a major concern particularly among the ageing population and their caregivers.[@R1] Although vitamin D is necessary for bone and muscle strength, the evidence on the role of vitamin D supplementation in preventing falls and fractures remains inconclusive.[@R2] The different doses and dosage schedules of vitamin D supplementation used in current RCTs have largely contributed to the conflicting evidence on the effectiveness of vitamin D supplementation for the primary prevention of falls and fractures among older adults.[@R6] Since the dosage amount and dosing schedule of vitamin D supplementation are important factors to consider when assessing the effects of vitamin D on skeletal health outcomes, it is imperative that guidance on the optimal doses and dosage schedules for the prevention of falls and fractures are provided.

This study is the first systematic review comparing steady dose and intermittent high-dose vitamin D dosage schedules. The results will provide comparative effectiveness of these two dosage schedules in relation to risk of falls and fractures among older adults (≥55 years). Our results will also provide comparative effectiveness and safety of the different supplementation schedules and dosage amounts. The results from this study will facilitate evidence-informed decision making and patient care and will serve as a clinical guideline towards effective dosing schedule for vitamin D in the primary prevention of falls and fractures among older adults.
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